MannKind Corporation to Acquire scPharmaceuticals: More Details Inside

MannKind Corporation (MNKD) will acquire scPharmaceuticals Inc. (SCPH) in a deal worth up to approximately $360 million, the companies announced on Monday.

Under the merger agreement, MannKind will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals common stock for $5.35 per share in cash at closing, in addition to one contingent value right worth up to $1. The non-tradeable CVR is payable upon achieving certain regulatory and net sales milestones, the companies said.

The total per-share consideration of up to $6.35 represents a premium of about 31% to SCPH’s closing price on Friday. The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.

On Stocktwits, retail sentiment around MannKind stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Meanwhile, sentiment around SCPH stock jumped from ‘neutral’ to ‘bullish’ territory, accompanied by ‘low’ levels of retail chatter. While shares of MannKind traded 5% lower in the pre-market session, SCPH stock traded 13% higher.

scPharmaceuticals currently markets Furoscix, an FDA-approved on-body infuser delivering Furosemide, used to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD). MannKind, which estimates Furoscix has a total addressable market of over $10 billion in the U.S., said that the acquisition will expand its reach into cardiorenal medicine.

MannKind also stated that the combined company is expected to have a stronger revenue base with three commercial assets, including Furoscix.

While MNKD stock is down by 36% this year, SCPH stock is up by 37%. 

Also See: Alibaba Stock Sees Retail Chatter Spike 340% Ahead Of Earnings: AI Investment And E-Commerce In Focus

For updates and corrections, email newsroom[at]stocktwits[dot]com